View Older Stories View More Recent Stories
-
LiquidSpace Launches API to Unite the Workspace Universe
-
SOASTA CEO Tom Lounibos to Speak at Leading Financial Conferences
-
BioBlast Pharma to Present at the 27th Annual ROTH Investor Conference
-
Roth Capital Maintains Trina Solar (TSL) at 'Buy' Following Q4 Numbers, Downstream Spin Plans
-
RestorGenex to Present at the 27th Annual ROTH Conference
-
Roth Capital Starts Celladon Corp (CLDN) at Buy
-
Form SC 13G Enerpulse Technologies, Filed by: ROTH CAPITAL PARTNERS, LLC
-
Vical to Present at the 27th Annual ROTH Conference
-
Vical to Present at the 27th Annual ROTH Conference
-
Streetinsider.com's Hot Lunchtime Reads 3/4: (KERX) (MCD) (RAX) (NLSN)
-
New Checkpoint Partnership Market TG Therapeutics' (TGTX) Entry into Immuno-Oncology Segment - Roth (CNDO)
-
Peer-Review Publications Continue Supporting Auryxia DIfferentiation - Roth Capital (KERX)
-
Xplore Tech (XPLR) 2M Offering Prices at $6/Share
-
Streetinsider.com's Hot Lunchtime Reads 3/3: (AAPL) (LL) (JKS) (TXN) (BOX)
-
Roth Capital Affirms JinkoSolar (JKS) at 'Buy'; Q4 Results Weak, but L-T Outlook Brightens
-
EVS to Present at the 27th Annual Roth Conference
-
Uranium Resources (URRE) Enters 4M Common Stock, 2M Warrants Placement
-
Alcobra Ltd. to Present at 27th Annual ROTH Conference
-
MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
-
Curis Announces Closing of Public Offering of Common Stock
-
Roth Capital Positive on Ligand Pharma (LGND); Kyprolis Met Primary Endpoint in ENDEAVOR Trial (AMGN)
-
Burcon to Present at the 27th Annual ROTH Conference on March 10, 2015
-
UBL Interactive to Present at 27th Annual ROTH Conference on March 9, 2015
-
Roth Capital Lowers FY15 Revs, GM Outlook on Ballard Power (BLDP); Maintains 'Buy' Rating
-
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Capital Downgrades Clayton Williams Energy (CWEI) to Neutral
-
I.D. Systems to Present at 27th Annual ROTH Conference on March 10, 2015
-
Roth Capital Trims PT on Keryx Biopharma (KERX) to $27; 'Blocking and Tacking' w/ Medicare to Ensure Auryxia Success
-
MoSys (MOSY) Prices 12.5M Common Offering at $1.60/Share
-
MoSys (MOSY) Poised to Open Lower Following Stock Offering
-
Roth Capital (SPPI) Comments on Spectrum (SPPI) Following Tentative FDA Approval of Sandoz's Levoleucovorin Calcium
-
Roth Positive on Expansion of STAR Study Sites; Afforms Cytori (CYTX) at 'Buy'
-
Notable Analyst Rating Changes 2/26: (AXP) (TMUS) (JAKK) Upgraded; (PCRX) (CVC) (PGRE) Downgraded
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Landec to Present at the 27th Annual ROTH Conference on March 10, 2015
-
Profire Energy to Present at 27th Annual ROTH Conference on March 10, 2015
-
Lion Biotechnologies (LBIO) Prices 8M Common Offering at $8/Share
-
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
-
Celldex Therapeutics Prices Public Offering of Common Stock
-
Roth Tweaks Numbers on Auryxia Ahead of Keryx Pharna's (KERX) Q4 Report; Maintains 'Buy' Rating
-
Upcoming Milestones, Key Investment Points for Bio Blast Pharma (ORPN) Being Missed by Investors - Roth Capital
-
Curis (CRIS) Prices 21.8M Common Offering at $2.75/Share
-
Curis Prices Public Offering of Common Stock
-
Curis Reports Fourth Quarter and Year-End 2014 Financial Results
-
Revolution Lighting Technologies to Present at 27th Annual ROTH Conference
-
Notable Analyst Rating Changes 2/23: (LH) (PENN) (CL) Upgraded; (BA) (RIG) (DGX) Downgraded
-
Breakthrough Designation for Celldex's (CLDX) Rintega Points to Stronger FDA Support as Cancer Vaccine in GBM - Roth Capital
-
Roth Capital Upgrades New Gold (NGD) to Neutral
-
Roth Capital Starts Flex Pharma (FLKS) at Buy
-
Roth Capital Starts Zosano Pharma (ZSAN) at Buy

